Although various biomarkers related to gliomas are used in clinical practice, such as O6-methylguanine-DNA methyltransferase (MGMT) and osteopontin (OPN), their sensitivity and specificity are debated (6, 7). This evidence concerns the gene SPP1 and central nervous system cancer.